Press Releases
| [+] |
September 22, 2011 Bristol-Myers Squibb and Ambrx Announce Collaboration for Novel Biologics Programs in Diabetes and Heart Failure PRINCETON, New Jersey, and LA JOLLA, California – September 22, 2011 – Bristol-Myers Squibb Company (NYSE: BMY) and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx’s research surrounding the Fibroblast Growth Factor 21 … Read More |
Articles
- April 1, 2005
Unnatural Amino Acid Could Prove Boon for Protein Therapeutics
Science Magazine - March 14, 2005
Giving Biotechnology A Chemical Push
Chemical & Engineering News - March 14, 2005
Watching Peptide Drugs Grow Up
Chemical & Engineering News - January 12, 2004
The Code Breakers
Bio-IT World - October 6, 2003
Executive Profile - RICHARD D. DIMARCHI
SD Business Journal (paid access) - September 29, 2003
Ambrx Inc. Lands $12.5M in First-Round Funding
SD Business Journal (paid access) - September 23, 2003
First-Round Financing of $12.5M Puts Ambrx On Development Path
BioWorld Today - September 22, 2003
Schultz seeks another success with Ambrx
The Daily Deal
